Brief: Autolus Therapeutics Announces Pivotal Phase 2 Felix Study Of Obe-Cel In Adult R/R B-All Selected For An Oral Presentation At Eha
12/05/2023 13:11
May 12 (Reuters) - Autolus Therapeutics PLC AUTL.O :
* AUTOLUS THERAPEUTICS ANNOUNCES PIVOTAL PHASE 2 FELIX STUDY
OF
OBE-CEL IN ADULT R/R B-ALL SELECTED FOR AN ORAL PRESENTATION AT
EHA
Source text for Eikon: ID:nGNX1KY6hF
Further company coverage: AUTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants